24/7 Wall St. on MSN50m
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
The Ozempic shortage is over, a big threat to off-brand weight loss drug sellers
In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, ...